1033822-52-4

Basic information

• Product Name: 5-phenethyl-1H-imidazol-2-ylamine
• Synonyms: 5-phenethyl-1H-imidazol-2-ylamine
• CAS NO: 1033822-52-4
• Molecular Weight: 187.244
• Mol File: 1033822-52-4.mol

Chemical Properties

• CAS DataBase Reference: 5-phenethyl-1H-imidazol-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-phenethyl-1H-imidazol-2-ylamine(1033822-52-4)
• EPA Substance Registry System: 5-phenethyl-1H-imidazol-2-ylamine(1033822-52-4)

Safety Data

• Hazardous Substances Data: 1033822-52-4(Hazardous Substances Data)

Upstream product

• 2550-26-7 4-Phenyl-2-butanone 
• 31984-10-8 1-bromo-4-phenylbutan-2-one 
• 1442469-17-1 N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide 

Relevant articles and documents

Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment

Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50 = 0.019 μM, rat IC50 = 0.0051 μM). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema.

IMIDAZOLE DERIVATIVES

The invention relates to imidazole derivatives which have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The invention also relates to a pharmaceutically-suitable acid-addition salt of the above compound. The invention further relates to a composition comprising an imidazole derivative as described above, or a pharmaceutically-suitable acid-addition salt thereof, and to processes for preparing such compounds.